YP
VKTX icon

YANKCOM Partnership’s Viking Therapeutics VKTX Stock Holding History

YANKCOM Partnership’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-2,358
Closed -$62K – 390
2025
Q3 		$62K Buy
2,358
+219
+10% +$6.53K 0.03% 177
2025
Q2 		$56.7K Buy
2,139
+1,006
+89% +$26.5K 0.03% 176
2025
Q1 		$27.4K Buy
1,133
+312
+38% +$9.86K 0.02% 198
2024
Q4 		$33K Buy
+821
New +$46.8K 0.02% 184

Other funds holding VKTX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

YANKCOM Partnership's VKTX Position: Q4 2025 in Review

YANKCOM Partnership sold out of Viking Therapeutics (VKTX) in Q4 2025, closing a stake of 2,358 shares — an estimated $62K sold.

YANKCOM Partnership first reported a position in VKTX in Q4 2024 and held it in 4 quarters. The position peaked at $62K in Q3 2025. 425 funds tracked by Wall St. Rank hold VKTX as of Q4 2025.

  • YANKCOM Partnership reported no remaining Viking Therapeutics position as of Q4 2025 after selling out during the quarter.
  • YANKCOM Partnership sold 2,358 Viking Therapeutics shares in Q4 2025, an estimated $62K.
  • YANKCOM Partnership first reported a position in Viking Therapeutics in Q4 2024 and held it in 4 quarters.
  • YANKCOM Partnership's Viking Therapeutics position peaked at $62K in Q3 2025.
  • 425 funds tracked by Wall St. Rank held Viking Therapeutics as of Q4 2025.

Based on YANKCOM Partnership's 13F filing for Q4 2025, filed 20 Jan 2026.